Last edition
News about "Holly Kordasiewicz"
Ionis Reports Positive Phase 3 FUSION Study Results
Ionis reports positive phase 3 FUSION results for ulefnersen, advancing a potential first disease-modifying treatment for FUS-ALS.
Holly Kordasiewicz | 24/09/2026 | By News Bureau
Ionis Completes Enrollment in Phase 3 REVEAL Study for Angelman Syndrome
Ionis has completed enrollment in the pivotal Phase 3 REVEAL study of obudanersen for Angelman syndrome, with topline clinical trial results expected in the second half of 2027.
Holly Kordasiewicz | 06/07/2026 | By Akanki | 328
Biogen Announces Topline Phase 2 Results for Diranersen in Early Alzheimer's Disease
Ionis partner Biogen announces topline phase 2 CELIA trial results for diranersen (BIIB080), showing reduced tau pathology and cognitive benefits in patients with early Alzheimer's Disease (AD).
Holly Kordasiewicz | 15/05/2026 | By News Bureau | 206
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy